EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Comparative pharmacodynamic analysis of resmetirom, semaglutide and obeticholic acid in translational mouse models of MASH

Rufeng Zhang, Xuecheng Li, Xiaoshuang Liang, Yuhuan Kuang, Xiangru Chen, Yunchao Niu, Ling Ye, Dirui Li, Xiaofei Zhou, Chunli Sun

Exploration of Endocrine and Metabolic Diseases · 2025

DOI: 10.37349/eemd.2025.101433 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Exploration of Endocrine and Metabolic Diseases, 2025. Verfasst von Rufeng Zhang und 9 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

This study aimed to evaluate and compare the therapeutic effects of resmetirom, semaglutide, and obeticholic acid (OCA) on non-alcoholic fatty liver disease (NAFLD) activity score (NAS) and fibrosis progression across three distinct metabolic dysfunction-associated steatohepatitis (MASH) models. A secondary objective was to assess model-specific variations in drug efficacy to inform future preclinical model selection for MASH research.

Methods

The Gubra-Amylin NASH (GAN) diet-induced obesity (DIO)-MASH model was induced by the GAN diet in C57BL/6 mice for 24 weeks, followed by semaglutide and resmetirom treatment for 4 weeks. The ob/ob-MASH model was induced by the GAN diet in ob/ob mice for 6 weeks, followed by semaglutide and resmetirom treatment for 4 weeks. GAN-carbon tetrachloride (CCL4) MASH model was induced by 10 weeks of GAN diet and followed by 4 weeks of CCL4 in C57BL/6 mice, resmetirom and OCA were given in the last 4 weeks. Body weights, serum biochemical markers [alanine aminotransferase (ALT), aspartate aminotransferase (AST), lipids], histopathological NAS scores, fibrosis staging, and α-smooth muscle actin (α-SMA) expression were analyzed.

Results

In the GAN DIO-MASH model, both semaglutide and resmetirom reduced NAS significantly, and resmetirom but not semaglutide reduced α-SMA expression. In the ob/ob MASH model, treatment with semaglutide and resmetirom reduced NAS. Semaglutide significantly reduced α-SMA expression. In the GAN-CCL4 MASH model, both resmetirom and OCA significantly reduced MASH progression, resmetirom reduced liver fibrosis and α-SMA expression while OCA reduced α-SMA expression only.

Conclusions

Resmetirom, semaglutide, and OCA exhibited model-dependent efficacy in attenuating MASH progression. Although all agents improved the NAS, their antifibrotic effects diverged significantly: resmetirom demonstrated pan-model efficacy, semaglutide selectively reduced α-SMA expression in leptin-deficient models, and OCA showed minimal impact on fibrosis biomarkers. These observations highlight the critical importance of preclinical model selection for MASH therapeutic development, particularly when assessing fibrosis-targeted interventions.

Zitieren

APA

Zhang, R., Li, X., Liang, X., Kuang, Y., Chen, X., Niu, Y., Ye, L., Li, D., Zhou, X., & Sun, C. (2025). Comparative pharmacodynamic analysis of resmetirom, semaglutide and obeticholic acid in translational mouse models of MASH. Exploration of Endocrine and Metabolic Diseases. https://doi.org/10.37349/eemd.2025.101433

Vancouver

Zhang R, Li X, Liang X, Kuang Y, Chen X, Niu Y, et al. Comparative pharmacodynamic analysis of resmetirom, semaglutide and obeticholic acid in translational mouse models of MASH. Exploration of Endocrine and Metabolic Diseases. 2025. doi:10.37349/eemd.2025.101433

BibTeX
@article{Zhang2025,
  author = {Zhang, Rufeng and Li, Xuecheng and Liang, Xiaoshuang and Kuang, Yuhuan and Chen, Xiangru and Niu, Yunchao and Ye, Ling and Li, Dirui and Zhou, Xiaofei and Sun, Chunli},
  title = {Comparative pharmacodynamic analysis of resmetirom, semaglutide and obeticholic acid in translational mouse models of MASH},
  journal = {Exploration of Endocrine and Metabolic Diseases},
  year = {2025},
  doi = {10.37349/eemd.2025.101433}
}
Kostenlos starten →